Edwards EVOQUE Tricuspid Valve Replacement System
Edwards Lifesciences, LLC · Decision date Oct 19, 2026
What did the FDA approve?
The FDA record for P230013/S029, dated 2026-10-19, describes an approved update to specifications for the Coated Capsule used with the Edwards EVOQUE Tricuspid Valve Replacement System. As stated, the change permits signs of delamination on the inner diameter of the proximal weld ring. The supplement is filed under the 135 review track for 30-day notice with reason listed as a process change involving a manufacturer, sterilizer, packager or supplier.
The identifier P230013 links this action to the original PMA of that number, and the S029 suffix indicates a supplement rather than a new approval of the whole system. The record does not specify the visual acceptance criteria, test methods, or limits applied to the delamination signs, nor does the stated purpose constitute independent evidence of safety or clinical effectiveness.
FDA approval order statement
Approval for updated specifications for the Coated Capsule to allow signs of delamination on the inner diameter of the proximal weld ring.
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 19, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230013/S029
- Regulatory pathway
- PMA supplement
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- Decision code
- APPR
- Decision date
- Oct 19, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.
- Applicant
- Edwards Lifesciences, LLC
- Product code
- NPW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230013 · Original PMA
Edwards EVOQUE Tricuspid Valve Replacement System
P230013/S029 received
Application receipt date recorded by FDA.
P230013/S027 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S029 · FDA decision
135 Review Track For 30-Day Notice
P230013/S033 · Related supplement
EVOQUE Tricuspid Valve Replacement System
P230013/S034 · Related supplement
Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)
Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Edwards Lifesciences, LLC | PMA approval | Feb 1, 2024 | FDA | |
EVOQUE Tricuspid Valve Replacement SystemP230013/S027 | Edwards Lifesciences, LLC | PMA supplement | Sep 16, 2026 | FDA |
EVOQUE Tricuspid Valve Replacement SystemP230013/S033 | Edwards Lifesciences, LLC | PMA supplement | Oct 21, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Edwards Lifesciences, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- One Edwards Way, Irvine, CA, 92614
Sources and methodology
- Original FDA record: P230013/S029
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records